288 related articles for article (PubMed ID: 21492074)
21. The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Heidegger I; Massoner P; Sampson N; Klocker H
Cancer Lett; 2015 Oct; 367(2):113-21. PubMed ID: 26231734
[TBL] [Abstract][Full Text] [Related]
22. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo.
Sharon C; Baranwal S; Patel NJ; Rodriguez-Agudo D; Pandak WM; Majumdar AP; Krystal G; Patel BB
Oncotarget; 2015 Jun; 6(17):15332-47. PubMed ID: 25895029
[TBL] [Abstract][Full Text] [Related]
24. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
25. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro.
Cardillo TM; Trisal P; Arrojo R; Goldenberg DM; Chang CH
BMC Cancer; 2013 Apr; 13():170. PubMed ID: 23548153
[TBL] [Abstract][Full Text] [Related]
26. Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Amin O; Beauchamp MC; Nader PA; Laskov I; Iqbal S; Philip CA; Yasmeen A; Gotlieb WH
BMC Cancer; 2015 Oct; 15():817. PubMed ID: 26510816
[TBL] [Abstract][Full Text] [Related]
27. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Camblin AJ; Pace EA; Adams S; Curley MD; Rimkunas V; Nie L; Tan G; Bloom T; Iadevaia S; Baum J; Minx C; Czibere A; Louis CU; Drummond DC; Nielsen UB; Schoeberl B; Pipas JM; Straubinger RM; Askoxylakis V; Lugovskoy AA
Clin Cancer Res; 2018 Jun; 24(12):2873-2885. PubMed ID: 29549161
[No Abstract] [Full Text] [Related]
28. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor.
Davaadelger B; Duan L; Perez RE; Gitelis S; Maki CG
Oncotarget; 2016 May; 7(19):27511-26. PubMed ID: 27050276
[TBL] [Abstract][Full Text] [Related]
29. Tanshinone I inhibits vascular smooth muscle cell proliferation by targeting insulin-like growth factor-1 receptor/phosphatidylinositol-3-kinase signaling pathway.
Wu YT; Bi YM; Tan ZB; Xie LP; Xu HL; Fan HJ; Chen HM; Li J; Liu B; Zhou YC
Eur J Pharmacol; 2019 Jun; 853():93-102. PubMed ID: 30878387
[TBL] [Abstract][Full Text] [Related]
30. Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.
Cao H; Dong W; Qu X; Shen H; Xu J; Zhu L; Liu Q; Du J
Sci Rep; 2016 Aug; 6():31072. PubMed ID: 27488947
[TBL] [Abstract][Full Text] [Related]
31. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
[TBL] [Abstract][Full Text] [Related]
32. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
[TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
34. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody.
Cao L; Yu Y; Darko I; Currier D; Mayeenuddin LH; Wan X; Khanna C; Helman LJ
Cancer Res; 2008 Oct; 68(19):8039-48. PubMed ID: 18829562
[TBL] [Abstract][Full Text] [Related]
35. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
[TBL] [Abstract][Full Text] [Related]
37. Targeting the type I insulin-like growth factor system for breast cancer therapy.
Sachdev D
Curr Drug Targets; 2010 Sep; 11(9):1121-32. PubMed ID: 20545608
[TBL] [Abstract][Full Text] [Related]
38. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
Kato H; Sekine Y; Furuya Y; Miyazawa Y; Koike H; Suzuki K
Biochem Biophys Res Commun; 2015 May; 461(1):115-21. PubMed ID: 25862373
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
Paz K; Hadari YR
Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
[TBL] [Abstract][Full Text] [Related]
40. Crosstalk between IGF-1R and other tumor promoting pathways.
Liu C; Zhang Z; Tang H; Jiang Z; You L; Liao Y
Curr Pharm Des; 2014; 20(17):2912-21. PubMed ID: 23944361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
